These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9515577)

  • 21. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
    Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
    Xu JM; Azzariti A; Tommasi S; Lacalamita R; Colucci G; Johnston PG; Church SW; Paradiso A
    Clin Colorectal Cancer; 2002 Nov; 2(3):182-8. PubMed ID: 12482336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
    Saltz LB; Kanowitz J; Kemeny NE; Schaaf L; Spriggs D; Staton BA; Berkery R; Steger C; Eng M; Dietz A; Locker P; Kelsen DP
    J Clin Oncol; 1996 Nov; 14(11):2959-67. PubMed ID: 8918493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
    Grivicich I; Mans DR; Peters GJ; Schwartsmann G
    Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
    Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Irinotecan in combination for colon cancer].
    Ducreux M; Gil-Delgado M; André T; Ychou M; de Gramond A; Khayat D
    Bull Cancer; 1998 Dec; Spec No():43-6. PubMed ID: 9932084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
    Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
    Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
    Cunningham D; Glimelius B
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):6-12. PubMed ID: 10213009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Camptothecin analogues with enhanced antitumor activity at acidic pH.
    Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
    Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells.
    Grem JL; Nguyen D; Monahan BP; Kao V; Geoffroy FJ
    Biochem Pharmacol; 1999 Aug; 58(3):477-86. PubMed ID: 10424768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
    Wu MH; Yan B; Humerickhouse R; Dolan ME
    Clin Cancer Res; 2002 Aug; 8(8):2696-700. PubMed ID: 12171903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
    Hennebelle I; Terret C; Chatelut E; Bugat R; Canal P; Guichard S
    Anticancer Drugs; 2000 Jul; 11(6):465-70. PubMed ID: 11001387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
    Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
    Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
    Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irinotecan (CPT-11): a brief overview.
    Rivory LP
    Clin Exp Pharmacol Physiol; 1996; 23(10-11):1000-4. PubMed ID: 8911750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
    Tanizawa A; Fujimori A; Fujimori Y; Pommier Y
    J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
    Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
    Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.